Filter by
-
UMB Dataset
Reporting of Drug Benefit in FDA-Approved Prescription Drug Labeling
- Authors
- Peter DoshiBansri DesaiKyungwan HongJohn H. Powers, III
- Description
Clinicians prescribing therapeutic agents newly approved by the FDA must rely on the information reported through drug labels (also known as “package inserts”). Ideally, labels should incorporate details regarding key efficacy information, including the magnitude of treatment benefit, and measures of precision and random error (confidence intervals and p values). This study assessed the degree to which...
- Subject
-
Drug Labeling/standards
- Access Rights
- Unrestricted access
-
UMB Dataset
Dataset for Communicating Nonefficacy Benefits of New Drugs Approved on the Basis of Noninferiority Trials Alone
- Authors
- Peter DoshiO'Mareen SpenceAida KuzucanJohn H. Powers, III
- Description
This dataset is the result of an investigation characterizing nonefficacy benefits of newly approved molecular entities (NMEs) based exclusively on noninferiority trials. Qualifying NMEs were identified using the FDA’s Novel Drug Approval website, sponsor press releases at market entry, FDA Drug Trials Snapshots, and statistical and medical officer reports. A total of 18 were selected for analysis....
- Subject
-
Drug IndustryEquivalence Trials as TopicHuman Experimentation/ethicsUnited States. Food and Drug Administration
- Access Rights
- Unrestricted access